RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.[1][2][3][4] It reached phase 1 clinical trials for this indication in 2010.[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.[1] The drug was developed by Hoffmann-La Roche.[1][2][4]
| Clinical data | |
|---|---|
| Other names | RG7351 |
| Drug class | Trace amine-associated receptor 1 (TAAR1) partial agonist |
See also
edit- Ralmitaront (RG-7906; RO-6889450)
- RG-7410
- Ulotaront (SEP-363856; SEP-856)
References
edit- ^ a b c d "RG 7351". AdisInsight. Springer Nature Switzerland AG. 5 November 2023. Retrieved 20 October 2024.
- ^ a b c "Delving into the Latest Updates on RG-7351 with Synapse". Synapse. 19 September 2024. Retrieved 20 October 2024.
- ^ Liu JF, Li JX (2018). "TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg". Frontiers in Pharmacology. 9: 279. doi:10.3389/fphar.2018.00279. PMC 5881156. PMID 29636691.
- ^ a b c Wu R, Liu J, Li JX (2022). "Trace amine-associated receptor 1 and drug abuse". Behavioral Pharmacology of Drug Abuse: Current Status. Adv Pharmacol. Vol. 93. pp. 373–401. doi:10.1016/bs.apha.2021.10.005. ISBN 978-0-323-91526-7. PMC 9826737. PMID 35341572.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |